Lowell, MA – According to filings with the U.S. Securities and Exchange Commission, Alcyone Therapeutics is raising $37,103,349.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, PJ Anand played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alcyone Therapeutics
Pioneering next-generation precision CNS genetic therapies. We are mission-driven to overcome the challenges in CNS therapy development through applying precision CNS delivery & dosing technologies to novel gene therapy technologies with a team of gene therapy and industry leaders. Alcyone’s four gene therapy platform technologies include X-reactivation, conventional transgene replacement, vectorized exon skipping and promotor modulation. The X-reactivation platform, which is used in our lead candidate, ACTX-101 for Rett syndrome, has the potential to become the gene therapy industry’s first pipeline within a product gene therapy, where the same gene product can be applied to potentially treating other X-related syndromes. Alcyone has developed a transformational CNS delivery technology platform that provides control of biodistribution to the targets of interest. This has the potential to move the frontier of the field by impacting safety, efficacy and potentially the amount of vectors needed for an effective therapy.

To learn more about Alcyone Therapeutics, visit http://alcyonetx.com/

Contact:
PJ Anand, Chief Executive Officer
978-709-1946
https://www.linkedin.com/in/pj-anand-424747/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved